These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31470091)

  • 1. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
    Olson R; Senan S; Harrow S; Gaede S; Louie A; Haasbeek C; Mulroy L; Lock M; Rodrigues G; Yaremko B; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman G; Warner A; Palma D
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):943-947. PubMed ID: 31470091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
    Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
    J Clin Oncol; 2020 Sep; 38(25):2830-2838. PubMed ID: 32484754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
    BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
    Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
    Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
    Harrow S; Palma DA; Olson R; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):611-616. PubMed ID: 35643253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
    Choi SH; Lee BM; Kim J; Kim DY; Seong J
    J Hepatol; 2024 Jul; 81(1):84-92. PubMed ID: 38467379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol.
    Palma DA; Giuliani ME; Correa RJM; Schneiders FL; Harrow S; Guckenberger M; Zhang T; Bahig H; Senthi S; Chung P; Olson R; Lock M; Raman S; Bauman GS; Lok BH; Laba JM; Glicksman RM; Nguyen TK; Lang P; Helou J; Goodman CD; Mendez LC; van Rossum PSN; Warner A; Gaede S; Allan AL
    BMC Palliat Care; 2024 Sep; 23(1):223. PubMed ID: 39244532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.
    Sutera P; Clump DA; Kalash R; D'Ambrosio D; Mihai A; Wang H; Petro DP; Burton SA; Heron DE
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):116-122. PubMed ID: 30149056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
    Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
    BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
    Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
    JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
    Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
    Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.
    Helou J; Thibault I; Chu W; Munoz-Schuffenegger P; Erler D; Rodrigues G; Warner A; Chan KKW; Chow E; Korol R; Davidson M; Chung HT
    Radiother Oncol; 2018 Dec; 129(3):435-440. PubMed ID: 30274721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.
    Palma DA; Haasbeek CJ; Rodrigues GB; Dahele M; Lock M; Yaremko B; Olson R; Liu M; Panarotto J; Griffioen GH; Gaede S; Slotman B; Senan S
    BMC Cancer; 2012 Jul; 12():305. PubMed ID: 22823994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.